Declaration of conflict of interest. None
|
|
- Meghan Kennedy
- 6 years ago
- Views:
Transcription
1 Declaration of conflict of interest None
2 Implantable cardioverter-defibrillator in patients with Chagas cardiomyopathy. Can we extrapolate results from the big trials? Dr. Santiago Nava Townsend National Institute of Cardiology Ignacio Chávez México City
3 CCM is a major cause of Morbidity in Latin America. Produces life threatening ventricular arrhythmias Ventricular conduction defects Scarring and fibrosis (apical aneurisms) SCD is the principal cause of death (55-65% of deaths). Incidence is estimated in 24 per 1000 pts/yr.
4 Facts ICD therapy reduces all cause mortality in pts with high risk of arrhythmic death. Secondary prevention of SCD in general, is accepted as a Class I indication. Thus ICD seems a very attractive therapy for primary and secondary prevention of SD in patients with Chagas disease.
5 n (%) x DE +/- Hombres 30(47.6) Mujeres 33(52.4) Edad promedio Fracción de Expulsión Diámetro Diastólico VI Diámetro Sistólico VI Aneurisma 6 (10) Extrasístoles Ventriculares 26(41) Fibrilación Auricular. 5(8) TVMS 17(27) TVMnS 14(22) Bloqueo AV 14(22) Trastornos H-P 49(77) Marcapaso 8(13) Taquicardia Ventricular en pacientes con Enfermedad de Chagas. Experiencia del Instituto Nacional de Cardiología Ignacio Chávez. Nava T. et al Con Taquicardia Sostenida S/TVMS P TVMSRIHH TVMSRD sup TVMSRD inf Total Hombres (n) ns Mujeres (n) ns Edad promedio ns Aneurisma (n) ns EV (n) FE promedio ns DDVI promedio ns DSVI promedio ns
6 Kaplan-Meier estimates for survival stratified for: no nonsustained ventricular tachycardia (NSVT) and no left ventricular (LV) dysfunction (group A): either NSVT or LV dysfunction (group B); and NSVT and LV dysfunction (group C) Rassi, A. et al. Circulation 2007;115:
7 Proposed algorithm to guide mortality risk assessment and therapeutic decision-making in patients with Chagas disease Rassi, A. et al. Circulation 2007;115:
8 Muratore C et al. PACE 1997; 20: Reported NO differences in outcomes in pts with ICD and Chagas vs Ischemic Cardiopathy. Martinelli Filho M et al. PACE 2000; 23: 1944 At 2 years, the cumulative probability of lifethreatening VA nonoccurrence was 0 in the Chagas' heart disease group versus 40% up to 55 months of follow-up in the non- Chagas disease group (P = ).
9 Appropriate shocks in 30 to 60%. 70% Supraventricular arrhythmias. 30% FV; 30 % TV. 60% Shocks, 60% ATP. 34% Mortality Probability of NO Therapy 9% per year 15% Arrhythmic storm Muratore CA. Europace. 2009;11: Cardinalli- Neto et al. J Cardiovasc Electrophysiol. 2007;18: Pacing Clin Electrophysiol. 2006; 29:
10 Muratore CA et al. Europace 2009; 11: ICD therapy provides protection by effectively terminating life-threatening arrhythmias in patients with Chagas' disease. This is especially so when patients receive the device for secondary prevention.
11 Marilelli M, et al. Am J Cardiol 2012; Jun 20 (Epub ahead of print). ICD efficacy in 2 nd : 116 pts, 42% EF, 7.1% annual mortality rate. 50% appr shocks, 11% inappropriate. Low EF and FNYHA III predictors of worst prognosis. Low cumulative RV pacing predictor of better outcome. Di Toro D, et al. Pacing Clin Electrophysiol 2011; 34: pts. 1 a P and 2 nd P. 60 yo, 40% EF, 10% one year mortality Age and LVEF predictors of mortality.
12 So is it the same? There are no randomized prospective evaluation of the safety and efficacy of ICD in CCM Only registries or small series of consecutive pts.
13 There is evidence questioning the ICD in CCM. Cardinalli-Neto et al. J Cardiovasc Electrofhysiol. 2007; 18: pts: 34% Mortality, 93% due to pomp failure Number of Shock per pt. Only independent predictor of mortality. Proarrhythmia due to VD pacing?, Shocks Cardiac function?? The most relevant clinical question is whether in a given condition the ICD reduces all cause mortality with an acceptable risk of complications and adverse effects compared with best medical therapy Anis Rassi. J Cardiovasc Electrophysiol. 2007; 18: 1241
14 Nava et al 38 61±1.3 68% 38±2.7 ICD+Amio 26% AS 45% Anis Rassi. J Cardiovasc Electrophysiol. 2007; 18: 1241
15 Primary Prevention Secondary Prevention R.B. Bestetti, A. Cardinalli-Neto / International Journal of Cardiology 2008; 131 : 9 17
16 CCM and ICD CCM and ICD in Mexico: 21 pts, 63% men, mean age 61 y/o. EF 30 ± % Secondary prevention (93% MVT) 15/21 pts had appropriate therapy. 246 episodes overall (1 61 episodes p/p) Arrhythmic storm in 42.9% Flores J. Nava S. et al. Arch Cardiol Mex. 2009; 79:263
17 Determinants of Arrhythmic Storm in Patients with CCM and ICD Flores J. Nava S. et al. Arch Cardiol Mex. 2009; 79:263 Cardiopatía Chagásica Crónica con TE (n=9) sin TE (n=12) P Edad NS Masculino 6 (46.2%) 7 (53.8%) NS Comorbilidades DM 1 (11.11%) 2 (16.6%) NS HAS 2 (22.2%) 2 (16.6%) NS Dislipidemia 2 (22.2%) 0 NS Tabaquismo AS is more frequent 3 (33.3%) in patients 4 (33.3%) with: NS Prevención Secundaria 8 (88.8%) 7 (58.3%) NS EF below 35% Tratamiento Médico Digitálico NYHA FC III/IV 8 (88.8%) 6 (50%) Diuréticos 8 (88.8%) 10 (83.3%) NS Lack of BB therapy IECAs 6 (66.6%) 11 (91.6%) NS Beta-bloq. 5 (55.5%) 12 (100%) 0.01 Estatina 0 0 NS Amiodarona 9 (100%) 11 (91.6%) NS FEVI Promedio 27.11% (+-3.6) 33% (+-3.51) NS FEVI <35% 8 (88.8%) 6 (50%) CF III-IV NYHA 6 (66.6%) 1 (8.3%) 0.01
18 Variable Chagas 38 CAD 38 Valor p Age ± ± 1.38 t=.231 TV CL µ ± DE ± ± t = QRS (ms) ± ± t = EF (%) ± ± 1.8 t =.596 LVDD(mm) ± ± 1.2 t = st Event (months) 3.25 ± ± 1.43 t = No of VT events Median 3 (min 1, max 8) Median 1 Min 1, max 4 ) U =.142 Sincope 15 (39) 4 (11) SD 5 (13 ) 6 (16) MVT 31 ( 81) 24 (63) 0.1 NYHA I 21 (55) 21 (55) II 14 (37) 10 ( 26) III 4 (10) 5 (13) IV 0 1 (3) NSVT( Holter) 29 ( 76) 22 (58) 0.003
19 Variable Chagas Isquémicos N (%) N (%) Valor p Modo de estimulación VVI 15 ( 40) 27 ( 71) DDD 22 ( 57) 7 ( 18) Biventricular 1 (3) 4 (11) Eventos detectados post implante de DAI 26 (68) 11 (29) Frecuencia de detección de la taquicardia TV1 ( < 160 lpm) TV2 ( 161 a 200 lpm) FV (> 200 lpm) 1 (3) 18 (47) 7 (18) 3 (8) 6 (16) 2 (5) Tormenta arrítmica 17 (45) 4 ( 11 ) Hospitalización por falla cardiaca 9 (23) 3 (8) Muerte 10 (26) 9 (24) 0.553
20 Observations: 80% had combined therapy (ATP + Shock) Only 20% responded to ATP alone. Some represent well tolerated VT s Nº of VT zones Increase number of Shocks? Deterioration of EF due to Shocks? Mortality 26%. No arrhythmic deaths 60% associated to CHF. 22% Mortality with AS vs 25% w/o AS.
21 Monomorphic Ventricular Tachycardia in patients With Chagasic Cardiomyopathy.
22 Monomorphic Ventricular Tachycardia in patients With Chagasic Cardiomyopathy.
23 Conclusions ICD indication in CCM should not be extrapolated from results of randomized studies obtained in patients with other conditions. Arrhythmic profile in CCM is different. High density of VT may emerge as a serious problem increasing de % of Arrhythmic storm. Frequent appropriate shocks may result in myocardial damage.
24 ICD persist as an attractive option in patients with CCM and unstable VT/VF or high risk evaluation for SCD. Indications should be made in individual basis. Randomized trials of adequate size comparing ICD with placebo or amiodarone will be able to identify the most appropriate management strategy in patients with CCM.
Do All Patients With An ICD Indication Need A BiV Pacing Device?
Do All Patients With An ICD Indication Need A BiV Pacing Device? Muhammad A. Hammouda, MD Electrophysiology Laboratory Department of Critical Care Medicine Cairo University Etiology and Pathophysiology
More informationShock Reduction Strategies Michael Geist E. Wolfson MC
Shock Reduction Strategies Michael Geist E. Wolfson MC Shock Therapy Thanks, I needed that! Why Do We Need To Reduce Shocks Long-term outcome after ICD and CRT implantation and influence of remote device
More informationAntiarrhythmic Drugs and Ablation in Patients with ICD and Shocks
Antiarrhythmic Drugs and Ablation in Patients with ICD and Shocks Alireza Ghorbani Sharif, MD Interventional Electrophysiologist Tehran Arrhythmia Clinic January 2016 Recurrent ICD shocks are associated
More informationRecurrent Implantable Defibrillator Discharges (ICD) Discharges ICD Storm
Recurrent Implantable Defibrillator Discharges (ICD) Discharges ICD Storm Guy Amit, MD, MPH Soroka University Medical Center Ben-Gurion University of the Negev Beer-Sheva, Israel Disclosures Consultant:
More informationLa gestione di un paziente con ICD: come evitare gli shock inappropriati e prolungare la sopravvivenza del paziente. Maurizio Gasparini
La gestione di un paziente con ICD: come evitare gli shock inappropriati e prolungare la sopravvivenza del paziente Maurizio Gasparini Responsabile UO Elettrofisiologia ed Elettrostimolazione Humanitas
More informationTachycardia Devices Indications and Basic Trouble Shooting
Tachycardia Devices Indications and Basic Trouble Shooting Peter A. Brady, MD., FRCP Cardiology Review Course London, March 6 th, 2014 2011 MFMER 3134946-1 Tachycardia Devices ICD Indications Primary and
More informationLong-Term Follow-Up of Implantable Cardioverter-Defibrillator for Secondary Prevention in Chagas Heart Disease
Long-Term Follow-Up of Implantable Cardioverter-Defibrillator for Secondary Prevention in Chagas Heart Disease Martino Martinelli, MD, PhD a, *, Sérgio Freitas de Siqueira, MSc Eng a, Eduardo Back Sternick,
More informationVentricular Tachycardia Ablation. Saverio Iacopino, MD, FACC, FESC
Ventricular Tachycardia Ablation Saverio Iacopino, MD, FACC, FESC ü Ventricular arrhythmias, both symptomatic and asymptomatic, are common, but syncope and SCD are infrequent initial manifestations of
More informationΠρόληψη του ΑΚΘ σε ασθενείς με μη-ισχαιμική μυοκαρδιοπάθεια:
Πρόληψη του ΑΚΘ σε ασθενείς με μη-ισχαιμική μυοκαρδιοπάθεια: Νεώτερα δεδομένα στη διαστρωμάτωση κινδύνου Εμμ. Μ. Κανουπάκης MD, PhD, FESC Πανεπιστημιακό Νοσοκομείο Ηρακλείου NIDCM Presence of LV dilatation
More informationΕμφύτευση απινιδωτών για πρωτογενή πρόληψη σε ασθενείς που δεν περιλαμβάνονται στις κλινικές μελέτες
Εμφύτευση απινιδωτών για πρωτογενή πρόληψη σε ασθενείς που δεν περιλαμβάνονται στις κλινικές μελέτες Δημήτριος M. Κωνσταντίνου Ειδικός Καρδιολόγος, MD, MSc, PhD, CCDS Πανεπιστημιακός Υπότροφος Dr. Konstantinou
More informationSudden Cardiac Death What an electrophysiologist thinks a cardiologist should know
Sudden Cardiac Death What an electrophysiologist thinks a cardiologist should know Steven J. Kalbfleisch, M.D. Medical Director Electrophysiology Laboratory Ross Heart Hospital Wexner Medical Center Sudden
More informationSubcutaneous Implantable Cardioverter Defibrillator (S-ICD)
Subcutaneous Implantable Cardioverter Defibrillator (S-ICD) D. D. MANOLATOS, MD, PhD, FESC Electrophysiology and Device Lab General Hospital Evangelismos, Athens The Problem: 300,000 people die each year
More informationPVCs: Do they cause Cardiomyopathy? Raed Abu Sham a, M.D.
PVCs: Do they cause Cardiomyopathy? Raed Abu Sham a, M.D. Cardiologist and Electrophysiologist No conflict of interest related to this presentation Objectives 1. PVCs are benign. What is the Evidence?
More informationCardiac Devices CRT,ICD: Who is and is not a Candidate? Who Decides
Cardiac Devices CRT,ICD: Who is and is not a Candidate? Who Decides Colette Seifer MB(Hons) FRCP(UK) Associate Professor, University of Manitoba, Cardiologist, Cardiac Sciences Program, St Boniface Hospital
More informationVentricular Arrhythmias
Presenting your most challenging cases Venice Arrhythmias Ventricular Arrhythmias Gioia Turitto, MD Presenter Disclosure Information A questionable indication for CRT-D in a patient with VT after successful
More informationICD Guidelines: who benefits from an ICD?
ICD Guidelines: who benefits from an ICD? Matthew Bennett Cardiac Electrophysiologist Vancouver Coastal Health, Device Lead Associate Professor, UBC Matthew.bennett@vch.ca Disclosures I have research collaborations
More informationImplantable Cardioverter Defibrillator Therapy in MADIT II Patients with Signs and Symptoms of Heart Failure
Implantable Cardioverter Defibrillator Therapy in MADIT II Patients with Signs and Symptoms of Heart Failure Wojciech Zareba Postinfarction patients with left ventricular dysfunction are at increased risk
More informationNeed to Know: Implantable Devices. Carolyn Brown RN, MN, CCRN Education Coordinator Emory Healthcare Atlanta, Georgia
Need to Know: Implantable Devices Carolyn Brown RN, MN, CCRN Education Coordinator Emory Healthcare Atlanta, Georgia Disclosure Statement I have no relationships to disclose. Objectives Discuss the most
More informationThe implantable cardioverter defibrillator is not enough: Ventricular Tachycardia Catheter Ablation in Patients with Structural Heart Disease
The implantable cardioverter defibrillator is not enough: Ventricular Tachycardia Catheter Ablation in Patients with Structural Heart Disease Paolo Della Bella, MD Arrhythmia Department and Clinical Electrophysiology
More informationEHRA Accreditation Exam - Sample MCQs Cardiac Pacing and ICDs
EHRA Accreditation Exam - Sample MCQs Cardiac Pacing and ICDs Dear EHRA Member, Dear Colleague, As you know, the EHRA Accreditation Process is becoming increasingly recognised as an important step for
More informationRisk Stratification of Sudden Cardiac Death
Risk Stratification of Sudden Cardiac Death Michael R Gold, MD, PhD Medical University of South Carolina Charleston, SC USA Disclosures: None Sudden Cardiac Death A Major Public Health Problem > 1/2 of
More informationThe Therapeutic Role of the Implantable Cardioverter Defibrillator in Arrhythmogenic Right Ventricular Dysplasia
The Therapeutic Role of the Implantable Cardioverter Defibrillator in Arrhythmogenic Right Ventricular Dysplasia By Sandeep Joshi, MD and Jonathan S. Steinberg, MD Arrhythmia Service, Division of Cardiology
More informationThe Role of ICD Therapy in Cardiac Resynchronization
The Role of ICD Therapy in Cardiac Resynchronization The Korean Society of Circulation 15 April 2005 Angel R. León, MD Carlyle Fraser Heart Center Division of Cardiology Emory University School of Medicine
More informationThe patient with electric storm
The complex patient in the cardiac care unit: The patient with electric storm Helmut U. Klein University of Rochester Medical Center Heart Research Follow-up Program and Isar Heart Center Muenchen Presenter
More informationSilvia G Priori MD PhD
The approach to the cardiac arrest survivor Silvia G Priori MD PhD Molecular Cardiology, IRCCS Fondazione Salvatore Maugeri Pavia, Italy AND Leon Charney Division of Cardiology, Cardiovascular Genetics
More informationReducing unnecessary and inappropriate therapy in secondary prevention patients
Reducing unnecessary and inappropriate therapy in secondary prevention patients Maurizio Gasparini, MD Chief of EP and Pacing Unit Humanitas Research Hospital, Rozzano-Milano Italy Goals of Optimal ICD
More informationWho does not need a primary preventive ICD?
Who does not need a primary preventive ICD? Hildegard Tanner, Bern Universitätsklinik für Kardiologie Disclosure of potential conflicts of interest Travel grants for educational purposes from: Biosense
More informationICD THERAPIES: are they harmful or just high risk markers?
ICD THERAPIES: are they harmful or just high risk markers? Konstantinos P. Letsas, MD, PhD, FESC LAB OF CARDIAC ELECTROPHYSIOLOGY EVANGELISMOS GENERAL HOSPITAL ATHENS ICD therapies are common In a meta-analysis
More informationSudden death as co-morbidity in patients following vascular intervention
Sudden death as co-morbidity in patients following vascular intervention Impact of ICD therapy Seah Nisam Director, Medical Science, Guidant Corporation Advanced Angioplasty Meeting (BCIS) London, 16 Jan,
More informationPrevention of Sudden Death in ARVC
ESC Munich, August 29, 2012 Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC): Prevention of Sudden Death in ARVC Thomas Wichter, MD, FESC Professor of Medicine - Cardiology Marienhospital Osnabrück
More informationCardiac Resynchronization ICD Therapy: What is New?
Cardiac Resynchronization ICD Therapy: What is New? Emile Daoud, MD Section Chief, Cardiac Electrophysiology Professor of Medicine The Ohio State University Normal Activation, Narrow QRS Synchrony Abnormal
More informationContinuous ECG telemonitoring with implantable devices: the expected clinical benefits
Continuous ECG telemonitoring with implantable devices: the expected clinical benefits C. W. Israel, M.D. Dept. of Cardiology Evangelical Hospital Bielefeld Germany Carsten.Israel@evkb.de Declaration of
More informationΔΠΔΜΒΑΣΙΚΗ ΘΔΡΑΠΔΙΑ ΚΟΙΛΙΑΚΩΝ ΑΡΡΤΘΜΙΩΝ
ΔΠΔΜΒΑΣΙΚΗ ΘΔΡΑΠΔΙΑ ΚΟΙΛΙΑΚΩΝ ΑΡΡΤΘΜΙΩΝ ΣΔΛΙΟ ΠΑΡΑΚΔΤΑÏΓΗ ΓΙΔΤΘΤΝΣΗ ΔΤ Α Καρδιολογική Κλινική ΑΠΘ, Νοζοκομείο ΑΧΕΠΑ, Θεζζαλονίκη NO CONFLICT OF INTEREST INTRODUCTION Sustained VT is an important cause
More informationWhen to ablate patients with premature ventricular complexes?
When to ablate patients with premature ventricular complexes? Nikolaos Fragakis Assistant Professor, FESC 3rd University Cardiology Department Hippokration Hospital, Thessaloniki 58 year-old female Case
More informationSummary, conclusions and future perspectives
Summary, conclusions and future perspectives Summary The general introduction (Chapter 1) of this thesis describes aspects of sudden cardiac death (SCD), ventricular arrhythmias, substrates for ventricular
More informationPrimary prevention of SCD with the ICD in Nonischemic Cardiomyopathy
Primary prevention of SCD with the ICD in Nonischemic Cardiomyopathy Michael R Gold, MD, PhD Medical University of South Carolina Charleston, SC USA Disclosures: Consulting and Clinical Trials Medtronic
More informationManagement of Syncope in Heart Failure. University of Iowa
Management of Syncope in Heart Failure Brian Olshansky University of Iowa 1 Syncope Transient loss of consciousness, with rapid, usually complete, recovery, with or without prodrome A common, non-specific,
More informationΕκθορηίζεις απινιδωηή και θνηηόηηηα: μέθοδοι μείωζης ηων θεραπειών απινίδωζης
Εκθορηίζεις απινιδωηή και θνηηόηηηα: μέθοδοι μείωζης ηων θεραπειών απινίδωζης Εμμ. Μ. Κανοσπάκης Καρδιολογική Κλινική Πανεπιζηημίοσ Κρήηης Lessons from large trials Conditioning Rhythm and Electrical Therapy
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Implantable cardioverter defibrillators for the treatment of arrhythmias and cardiac resynchronisation therapy for the treatment of heart failure (review
More informationEndpoints When Treating VT/VF in Patients with ICDs Programming Wojciech Zareba, MD, PhD
Endpoints When Treating VT/VF in Patients with ICDs Programming Wojciech Zareba, MD, PhD Professor of Cardiology/Medicine Director of the Heart Research Follow Up Program, University of Rochester, Rochester,
More informationCatheter ablation of monomorphic ventricular tachycardia. Department of Cardiology, IKEM, Prague, Czech Republic
Catheter ablation of monomorphic ventricular tachycardia Department of Cardiology, IKEM, Prague, Czech Republic DECLARATION OF CONFLICT OF INTEREST None Ventricular tachycardia ablation in IKEM, Prague
More informationRecurrent refractory ventricular tachycardia in a patient with LVAD
Monster Cases Recurrent refractory ventricular tachycardia in a patient with LVAD Maurizio Lunati MD Director SC Cardiologia 3 Elettrofisiologia Chairman De Gasperis Cardio Center Department ASST G.O.M.
More informationDevice Interrogation- Pacemakers, ICD and Loop Recorders. Dulce Obias-Manno, RN, MHSA, CCDS,CEPS, FHRS Device Clinic Coordinator, MHVI
Device Interrogation- Pacemakers, ICD and Loop Recorders Dulce Obias-Manno, RN, MHSA, CCDS,CEPS, FHRS Device Clinic Coordinator, MHVI Disclosures Consultant: Medtronic Speaker s Bureau: St. Jude Medical
More informationICD Therapy. Disclaimers
ICD Therapy Rodney Horton, MD Texas Cardiac Arrhythmia Institute Texas Cardiovascular, PA Austin, TX Speaker s Bureau St. Jude Medical Medtronic Boston Scientific Disclaimers Clinical Advisory Panel St.
More informationVentricular tachycardia and ischemia. Martin Jan Schalij Department of Cardiology Leiden University Medical Center
Ventricular tachycardia and ischemia Martin Jan Schalij Department of Cardiology Leiden University Medical Center Disclosure: Research grants from: Boston Scientific Medtronic Biotronik Sudden Cardiac
More informationJean François Leclercq Department of Rythmology Private Hospital of Parly 2 - Le Chesnay F
SECONDARY PREVENTION of Sudden Death: in which patients? Jean François Leclercq Department of Rythmology Private Hospital of Parly 2 - Le Chesnay F Why an AID is effective? Because it stoppes a VT very
More informationDevice Update Implantable Cardioverter Defibrillator (ICD) 박상원
2012 년춘계학술대회 Device Update Implantable Cardioverter Defibrillator (ICD) 박상원 Arrhythmia Center, KUMC www.korea-heartrhythm.com Korea University Medical Center Seoul, Korea The Development of ICD by a team
More informationTehran Arrhythmia Center
Tehran Arrhythmia Center The Worst Scenario A 4 year old kid High heart rates first noted by parents at 20 months of age. Family physician detected rates as high as 220 bpm at that age. He was visited,
More informationDipartimento di Scienze Cardiovascolari Università Campus Bio-Medico di Roma Dott. Vito Calabrese
Dipartimento di Scienze Cardiovascolari Università Campus Bio-Medico di Roma Dott. Vito Calabrese Because the primary objective was cure symptomatic bradicardya due to syncope Because this is the common
More informationLifeVest. Sven Reek, Aarau. Conflict of interest: none
LifeVest Sven Reek, Aarau Conflict of interest: none WCD (LifeVest, ZOLL, Pittsburg,PA) Technical aspects Wearable garment with 4 dry ECG electrodes (detection) 3 defibrillation pads External defibrillator
More information3/23/2018. Complications of VAD Therapy: Arrhythmias. Disclosures. Agenda. I have no relevant disclosures
March 23, 2018 Complications of VAD Therapy: Arrhythmias Sandeep M. Jani, MD, MPH Associate Directory of Advanced Heart Failure and Population Health MedStar Heart and Vascular Institute - Baltimore Sandeep
More informationDefibrillation threshold testing should no longer be performed: contra
Defibrillation threshold testing should no longer be performed: contra Andreas Goette St. Vincenz-Hospital Paderborn Dept. of Cardiology and Intensive Care Medicine Germany No conflict of interest to disclose
More informationLarge RCT s of CRT 2002 to present
Have We Expanded Our Use of CRT for Heart Failure Patients? Sana M. Al-Khatib, MD, MHS Associate Professor of Medicine Electrophysiology Section- Division of Cardiology Duke University Potential Conflicts
More informationSeveral studies of the primary prevention. Original Research
Original Research Hellenic J Cardiol 2015; 56: 230-236 Inducibility of Ventricular Arrhythmia and Tachyarrhythmia Recurrences in Patients with Implantable Defibrillator Giuseppe Stabile 1, Paolo Gallo
More informationICD. Guidelines and Critical Review of Trials. Win K. Shen, MD Professor of Medicine Mayo Clinic College of Medicine Mayo Clinic Arizona Torino 2011
ICD Guidelines and Critical Review of Trials Win K. Shen, MD Professor of Medicine Mayo Clinic College of Medicine Mayo Clinic Arizona Torino 2011 Disclosure Relevant Financial Relationship(s) None Off
More informationThe Heart Is A Muscle Too! The Cardiomyopathy In Duchenne Muscular Dystrophy
The Heart Is A Muscle Too! The Cardiomyopathy In Duchenne Muscular Dystrophy Linda Cripe MD Professor of Pediatrics Nationwide Children s Hospital/The Ohio State University.... Why are cardiologists
More informationResponse of Right Ventricular Size to Treatment with Cardiac Resynchronization Therapy and the Risk of Ventricular Tachyarrhythmias in MADIT-CRT
Response of Right Ventricular Size to Treatment with Cardiac Resynchronization Therapy and the Risk of Ventricular Tachyarrhythmias in MADIT-CRT Heart Rhythm Society (May 11, 2012) Colin L. Doyle, BA,*
More informationDevice detected VT: How much VT is significant and is VT ablation the answer?
Device detected VT: How much VT is significant and is VT ablation the answer? Dr Mark Mason Harefield Hospital Royal Brompton and Harefield NHS Foundation Trust What is VT (in this context)? What is VT?
More informationArrhythmias Focused Review. Who Needs An ICD?
Who Needs An ICD? Cesar Alberte, MD, Douglas P. Zipes, MD, Krannert Institute of Cardiology, Indiana University School of Medicine, Indianapolis, IN Sudden cardiac arrest is one of the most common causes
More informationArrhythmias and Heart Failure Dr Chris Lang Consultant Cardiologist and Electrophysiologist Royal Infirmary of Edinburgh
Arrhythmias and Heart Failure Dr Chris Lang Consultant Cardiologist and Electrophysiologist Royal Infirmary of Edinburgh Arrhythmias and Heart Failure Ventricular Supraventricular VT/VF Primary prevention
More informationSupplementary Online Content
Supplementary Online Content Tseng ZH, Hayward RM, Clark NM, et al. Sudden death in patients with cardiac implantable electronic devices. JAMA Intern Med. Published online June 22, 2015. doi:10.1001/jamainternmed.2015.2641.
More informationAssessment of Defibrillation Threshold upon Implantable Cardioverter-Defibrillator implant in Relation to patient s prognosis
Assessment of Defibrillation Threshold upon Implantable Cardioverter-Defibrillator implant in Relation to patient s prognosis Investigator: Keiko Saito, MD Mentor: Yuji Saito, MD, PhD, FACP, FACC Department
More informationPrimary prevention ICD recipients: the need for defibrillator back-up after an event-free first battery service-life
Chapter 3 Primary prevention ICD recipients: the need for defibrillator back-up after an event-free first battery service-life Guido H. van Welsenes, MS, Johannes B. van Rees, MD, Joep Thijssen, MD, Serge
More informationOriginal Article Predictors of appropriate ICD therapy in patients with implantable cardioverter-defibrillator
www.ipej.org 17 Original Article Predictors of appropriate ICD therapy in patients with implantable cardioverter-defibrillator Mohammad Reza Dehghani, M.D.*, Arash Arya, M.D.*, Majid Haghjoo, M.D., Zahra
More informationAtrial fibrillation: why it's important to make opportunities diagnosis in single chamber ICD patients
ADVANCES IN CARDIAC ARRHYTHMIAS and GREAT INNOVATIONS IN CARDIOLOGY Turin October 13-15, 2016 Atrial fibrillation: why it's important to make opportunities diagnosis in single chamber ICD patients Dott.
More informationNew scientific documents from EHRA Management of patients with defibrillator shocks
New scientific documents from EHRA Management of patients with defibrillator shocks Frieder Braunschweig MD PhD FESC Karolinska University Hospital Stockholm, Sweden Evolution of ICD therapy Worldwide
More informationMADIT Studies: CRT in the Non-LBBB Patient and Other Findings. Arthur J. Moss, MD
MADIT Studies: CRT in the Non-LBBB Patient and Other Findings Arthur J. Moss, MD University of Rochester Medical Cntr. Rochester, NY 13 th Annual New Frontiers in Heart Failure Rx NYC, NY January 26, 2013
More informationEfficacy and safety of implantable cardioverterdefibrillators in patients with Chagas disease
Europace (2013) 15, 957 962 doi:10.1093/europace/eut011 CLINICAL RESEARCH Sudden death and ICDs Efficacy and safety of implantable cardioverterdefibrillators in patients with Chagas disease Marco Paulo
More informationEffect of cardiac resynchronization therapy on the incidence of electrical storm
International Journal of Cardiology 143 (2010) 330 336 www.elsevier.com/locate/ijcard Effect of cardiac resynchronization therapy on the incidence of electrical storm Peter Nordbeck, Bernhard Seidl, Beatrix
More informationNovel Approaches to VT Management Glenn M Polin MD
Novel Approaches to VT Management Glenn M Polin MD Medical Director, Electrophysiology Laboratory John Ochsner Heart and Vascular Institute New Orleans, LA Disclosures Pfizer Speaker Bureau Bristol Myers
More informationTech Corner. ATP in the Fast VT zone
Tech Corner ATP in the Fast VT zone NOTE: PLEASE NOTE THAT THE FOLLOWING INFORMATION IS A GENERAL DESCRIPTION OF THE FUNCTION. DETAILS AND PARTICULAR CASES ARE NOT DESCRIBED IN THE ARTICLE. FOR ADDITIONAL
More informationInteresting EP Cases Catheter ablation to treat congestive heart failure (CHF)
Interesting EP Cases Catheter ablation to treat congestive heart failure (CHF) Yiming WU, MD, PhD. Alaska heart and vascular institute. ywu@alaskaheart.com 907-561-3211 19 yo man transferred for out side
More informationSUBCUTANEOUS ICD ITS JOURNEY FROM PROOF OF CONCEPT TO CURRENT EVOLUTION
SUBCUTANEOUS ICD ITS JOURNEY FROM PROOF OF CONCEPT TO CURRENT EVOLUTION Giovanni Luca Botto MD, FEHRA, FESC Electrophysiology Unit ASST Lariana, Como, Italy Presenter Disclosure Information Research support:
More informationSynopsis of Management on Ventricular arrhythmias. M. Soni MD Interventional Cardiologist
Synopsis of Management on Ventricular arrhythmias M. Soni MD Interventional Cardiologist No financial disclosure Premature Ventricular Contraction (PVC) Ventricular Bigeminy Ventricular Trigeminy Multifocal
More informationICD: Basics, Programming and Trouble-shooting
ICD: Basics, Programming and Trouble-shooting Amir AbdelWahab, MD Electrophysiology and Pacing Service Cardiology Department Cairo University Feb 2013 Evolution of ICD Technology ICD Evolution Indications
More informationCONTAK RENEWAL 3 AVT CLINICAL SUMMARY
CAUTION: Federal law restricts this device to sale by or on the order of a physician trained or experienced in device implant and follow-up procedures. CLINICAL SUMMARY CONTAK RENEWAL 3 AVT Boston Scientific
More informationImplantable cardioverter defibrillator therapy in grown-up patients with transposition of the great arteries role of anti-tachycardia pacing
Original Article Implantable cardioverter defibrillator therapy in grown-up patients with transposition of the great arteries role of anti-tachycardia pacing Stephan Hohmann 1, David Duncker 1, Thorben
More informationCONTAK CD CLINICAL SUMMARY
CAUTION: Federal law restricts this device to sale by or on the order of a physician trained or experienced in device implant and follow-up procedures. CLINICAL SUMMARY CONTAK CD Boston Scientific Corporation
More informationΕνδείξεισ εμφύτευςησ απινιδωτή ςτην «γκρίζα ζώνη» Γεώργιοσ Ανδρικόπουλοσ, MD, PhD, Αν. Δ/ντήσ Καρδιολογικήσ Κλινικήσ ΓΝΑ «Ερρίκοσ Ντυνάν»
Ενδείξεισ εμφύτευςησ απινιδωτή ςτην «γκρίζα ζώνη» Γεώργιοσ Ανδρικόπουλοσ, MD, PhD, Αν. Δ/ντήσ Καρδιολογικήσ Κλινικήσ ΓΝΑ «Ερρίκοσ Ντυνάν» Major Implantable Cardioverter-Defibrillator Trials for Prevention
More informationWhen to implant an ICD in systemic right ventricle?
When to implant an ICD in systemic right ventricle? Département de rythmologie et de stimulation cardiaque Nicolas Combes n.combes@clinique-pasteur.com Pôle de cardiologie pédiatrique et congénitale Risk
More informationthat number is extremely high. It s 16 episodes, or in other words, it s 14, one-four, ICD shocks per patient per day.
Doctor Karlsner, Doctor Schumosky, ladies and gentlemen. It s my real pleasure to participate in this session on controversial issues in the management of ventricular tachycardia and I m sure that will
More informationThe patient with (without) an ICD and heart failure: Management of electrical storm
ISHNE Heart Failure Virtual Symposium April 2008 The patient with (without) an ICD and heart failure: Management of electrical storm Westfälische Wilhelms-Universität Münster Günter Breithardt, MD, FESC,
More informationArrhythmia/Electrophysiology
Arrhythmia/Electrophysiology Are Implantable Cardioverter Defibrillator Shocks a Surrogate for Sudden Cardiac Death in Patients With Nonischemic Cardiomyopathy? Kenneth A. Ellenbogen, MD; Joseph H. Levine,
More informationCRT-D or CRT-P: HOW TO CHOOSE THE RIGHT PATIENT?
CRT-D or CRT-P: HOW TO CHOOSE THE RIGHT PATIENT? Alessandro Lipari, MD Chair and Department of Cardiology University of Study and Spedali Civili Brescia -Italy The birth of CRT in Europe, 20 years ago
More informationINNOVATIONS IN DEVICE THERAPY:
INNOVATIONS IN DEVICE THERAPY: Subcutaneous ICDs, Leadless Pacemakers, CRT Indications David J Wilber MD Loyola University Medical Center Disclosures: ACC Foundation: Consultant; Biosense / Webster: Consultant,
More informationElectrical Storm in Coronary Artery Disease. Saeed Oraii MD, Cardiologist Interventional Electrophysiologist Tehran Arrhythmia Clinic July 2016
Electrical Storm in Coronary Artery Disease Saeed Oraii MD, Cardiologist Interventional Electrophysiologist Tehran Arrhythmia Clinic July 2016 48 yrs. Old diabetic with ACS 48 yrs. Old diabetic with ACS
More informationQRS Duration Does Not Predict Occurrence of Ventricular Tachyarrhythmias in Patients With Implanted Cardioverter-Defibrillators
Journal of the American College of Cardiology Vol. 46, No. 2, 2005 2005 by the American College of Cardiology Foundation ISSN 0735-1097/05/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.03.060
More informationProphylactic ablation
Ventricular tachycardia in ischaemic heart disease. Update on electrical therapy 29 august 2010 Prophylactic ablation Pasquale Notarstefano Cardiovacular Department S. Donato Hospital, Arezzo (IT) Prophylactic
More informationSecondary prevention of sudden cardiac death
Secondary prevention of sudden cardiac death Balbir Singh, MD, DM; Lakshmi N. Kottu, MBBS, Dip Card, PGPCard Department of Cardiology, Medanta Medcity Hospital, Gurgaon, India Abstract All randomised secondary
More informationDevice based CRT optimization: is there a future? Lessons learned from published trials
Device based CRT optimization: is there a future? Lessons learned from published trials C. Leclercq Department of Cardiology Centre Cardio-Pneumologique Rennes, France Presenter Disclosure Information
More informationHeart Rhythm Disorders. How do you quantify risk?
Heart Rhythm Disorders How do you quantify risk? Heart Rhythm Disorders Scale of the Problem 1/2 population will have an episode of transient loss of consciousness (T-LOC) at some stage in their life.
More informationPreventing Sudden Death Current & Future Role of ICD Therapy
Preventing Sudden Death Current & Future Role of ICD Therapy Derek V Exner, MD, MPH, FRCPC, FACC, FAHA, FHRS Professor, Libin Cardiovascular Institute of Alberta Canada Research Chair, Cardiovascular Clinical
More informationDual-Chamber Implantable Cardioverter-Defibrillator
February 1998 9 Dual-Chamber Implantable Cardioverter-Defibrillator A.SH. REVISHVILI A.N. Bakoulev Research Center for Cardiovascular Surgery, Russian Academy of Medical Sciences, Moscow, Russia Summary
More informationDevices and Other Non- Pharmacologic Therapy in CHF. Angel R. Leon, MD FACC Division of Cardiology Emory University School of Medicine
Devices and Other Non- Pharmacologic Therapy in CHF Angel R. Leon, MD FACC Division of Cardiology Emory University School of Medicine Disclosure None University of Miami vs. OSU Renegade Miami football
More informationRisk Stratification in Non-Compaction Cardiomyopathy. Who Should Get an ICD or CRT-D? Prof. Néstor Galizio
Risk Stratification in Non-Compaction Cardiomyopathy. Who Should Get an ICD or CRT-D? (COMPAS Registry) Prof. Néstor Galizio Director of the Electrophysiology Division University Hospital - Favaloro Foundation
More informationCase Report Mitral Subvalvular Aneurysm in a Patient with Chagas Disease and Recurrent Episodes of Ventricular Tachycardia
Case Reports in Cardiology Volume 2015, Article ID 213104, 5 pages http://dx.doi.org/10.1155/2015/213104 Case Report Mitral Subvalvular Aneurysm in a Patient with Chagas Disease and Recurrent Episodes
More informationSubcutaneous ICD Emerging Role of Sudden Cardiac Death Prevention
Subcutaneous ICD Emerging Role of Sudden Cardiac Death Prevention Dr Ngai-Yin Chan, MBBS, FRCP(Lond), FRCP(Edin), FRCP(Glasg), FACC, FHRS, Consultant Physician, Department of Medicine & Geriatrics, Princess
More informationProgramming of Bradycardic Parameters. C. W. Israel, M.D. Dept. of Cardiology Evangelical Hospital Bielefeld Germany
Programming of Bradycardic Parameters C. W. Israel, M.D. Dept. of Cardiology Evangelical Hospital Bielefeld Germany Carsten.Israel@evkb.de Programming of ICD Brady Parameters Conflict of Interest Biotronik
More informationSyncope in Heart Failure Patients How to judge and treat? Jean-Claude Deharo, MD, FESC Marseilles, France
Syncope in Heart Failure Patients How to judge and treat? Jean-Claude Deharo, MD, FESC Marseilles, France Syncope in advanced heart failure: high risk of sudden death N = 491 patients with HF (NYHA III-IV)
More informationCommon clinical dilemmas in AF. Dr. Santiago Nava Townsend
Common clinical dilemmas in AF Dr. Santiago Nava Townsend Case presentation Male, 40 years old, Apparently no risk factors for CV disease History of palpitations since age 20, very sporadic and very short
More information